Thursday, September 17, 2020
Medovate – a pioneering medical device development company specialising in anaesthesia, airway management, critical care, and surgery – announced it has received CE Mark Approval for its game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia).
SAFIRA® is a revolutionary new technology that transforms regional anaesthesia into a one-person procedure, putting control in the hands of the anaesthetist.
The Class II medical device provides a unique safety solution that monitors and limits injection pressure, helping to improve patient safety by reducing the risk of nerve damage following injection. In addition, economic modelling shows it has the potential to generate significant time and cost savings.
Developed in collaboration with anaesthetists in the UK National Health Service (NHS), the device was successfully launched in the US earlier this year, having secured FDA clearance, bringing Medovate’s first medtech innovation to market.
Successful CE certification marks a key milestone for the fast-growing company, itself established just over two years ago. As a UK-based enterprise, this regulatory approval is essential as it continues to expand in territories across the world.
Alan Finnerty, Technology Director, Medovate commented: "We are thrilled to announce CE mark approval for our pioneering technology. Given the significant benefits SAFIRA® brings to both clinicians and patients, we are confident that our ability to enter the European market will help deliver improved outcomes for patients undergoing regional anaesthesia procedures, as well as
generate unique cost optimisation benefits for healthcare."
Stuart Thomson, Managing Director, Medovate commented "SAFIRA® CE certification is an important leap forward for our company as we continue to expand our footprint and presence globally. The entire Medovate team have worked extremely hard to deliver both US FDA clearance and EU CE approval for this technology within the last six months.
Our goal is to provide clinicians with an innovative solution to carry out regional anaesthesia procedures effectively at safer pressures. This is especially important in the current healthcare climate which is facing many challenges."
The European and American Societies of Regional Anaesthesia have recently produced joint COVID-19 recommendations stating that regional anaesthesia should be preferred over general anaesthesia whenever surgery is planned for suspected or confirmed COVID-19 patients. This is because regional anaesthesia, which involves numbing only the area of the body that requires surgery, preserves respiratory function and avoids aerosolisation and the potential for transmission of COVID-19 compared to general anaesthesia. In enabling regional anaesthesia to be carried out as a one-person procedure, Medovate’s innovative technology, SAFIRA®, further compliments these recent recommendations.
Now, with both CE Mark Approval and FDA Clearance, SAFIRA® can be readily integrated into healthcare markets across Europe and the US.
For further information or visuals of SAFIRA, please contact: Julia Price julia@juliaprice.co.uk, 07737864878
Note to Editors:
About Medovate www.medovate.co.uk
Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond. Medovate identifies and works with high potential medtech innovations, providing the specialist management and technical resources, along with finance required to lead innovation development through clinical trials and regulatory approval. By providing funding and support at a crucial point in the development of innovative medical technologies, Medovate accelerates innovations to market in order to benefit
patient care and healthcare delivery. The company has a strong portfolio relating to specialisms in anaesthesia, airway management, critical care and surgery. Medovate directly benefits the NHS by:
